Samsung Biologics Reports Fourth Quarter and Fiscal Year 2023 Financial Results

• Recorded Q4’23 consolidated revenue of KRW 1.07 trillion and Q4’23 operating profit of KRW 350 billion

• Recorded FY’23 consolidated revenue of KRW 3.69 trillion and FY’23 operating profit of KRW 1.1 trillion

• Exceeded KRW 1 trillion consolidated operating income for the first time, underscoring over a decade of operational excellence

Incheon, S. Korea, January 24, 2024 – Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced robust financial results for the fourth quarter and fiscal year 2023. 

"We have achieved another remarkable milestone with our consolidated operating profit surpassing KRW 1 trillion in the 12 years since our founding in 2011. Our unwavering commitment to customer-centric services and continuous innovation remains at the core of our mission, ensuring the delivery of high-quality biomedicines to patients worldwide,” said John Rim, CEO and President of Samsung Biologics. “Despite the challenging environment, we remain optimistic, anticipating continued growth driven by sustained partnerships, expanded capacity, and strategic portfolio diversification in the coming year." 

On a standalone basis, Samsung Biologics recorded a revenue of KRW 2.94 trillion and operating profit of KRW 1.2 trillion in 2023. In the fourth quarter of 2023 alone, the company posted a revenue of KRW 827.9 billion and operating profit of KRW 334.0 billion.

FISCAL YEAR 2024 OUTLOOK

Building on this momentum, Samsung Biologics plans to continue making strategic investments in expanding capacity and global reach, while enhancing capabilities to better meet clients' evolving needs.

With Plant 4's full operation, commenced in 2023 as previously committed, the increased production capacity is expected to gradually enhance its contribution to future revenue. Having successfully completed engineering run and Process Performance Qualification (PPQ), and obtained regulatory approval for large-scale production, Plant 4 is projected to contribute approximately 30% of drug substance manufacturing business revenue by 2025. Plant 5, the first facility of the company’s second Bio Campus, is set to begin operations in April 2025, five months ahead of its initial construction timeline.

To accommodate each client’s ever-evolving needs, Samsung Biologics introduced customized CMC solutions: three development packages designed to ensure maximum flexibility and meet clients’ goals per their development stage. The company’s newly launched development platforms, S-CHOsient™ and S-Glyn™, will also help ensure successful development with higher productivity and quality. 

In an effort to diversify its business portfolio, the company's separate antibody-drug conjugate (ADC) manufacturing facility is set to be cGMP-ready within 2024, enabling the exploration of innovative technologies for next-generation biomedicines. This aligns with investments the company has made through the Samsung Life Science Fund, supporting pioneering biotechs like AimedBio and Araris Biotech AG in ADC technology.

Samsung Biologics also continues to engage and drive action in the sustainability front. As a member of the Sustainable Markets Initiative’s Health Systems Task Force, Samsung Biologics, along with 13 other global public-private health system leaders, has committed to bringing practical solutions to decarbonizing healthcare supply chains. The company will further strengthen partnerships with suppliers to foster collaboration, while continuing to establish a concrete roadmap for ESG management. Recently, Samsung Biologics was awarded the EcoVadis’ Platinum Sustainability Rating, the highest recognition given, for the company’s sustainable management practices.

For more details on performance and financials, please refer to the Earnings Release.